Evidence map›Paper›PMID 35255093›Full record

ArticlePLoS neglected tropical diseases2022

Pan-ebolavirus serology study of healthcare workers in the Mbandaka Health Region, Democratic Republic of the Congo.

Kelly C L Shaffer, Sean Hui, Anna Bratcher, Liam B King, Rachel Mutombe, Nathalie Kavira, Jean Paul Kompany, Merly Tambu, Kamy Musene, Patrick Mukadi and 9 more

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 2 countries.

Kelly C L ShafferCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, United States of America.ORCID 0000-0002-6212-1428
Sean HuiCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, United States of America.ORCID 0000-0002-9870-6823
Anna BratcherDepartment of Epidemiology, UCLA Fielding School of Public Health, University of California, Los Angeles, Los Angeles, California, United States of America.ORCID 0000-0001-5972-1249
Liam B KingCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, United States of America.ORCID 0000-0003-3544-1941
Rachel MutombeInstitut National de Recherche Biomedicale, Kinshasa, Democratic Republic of the Congo.
Nathalie KaviraInstitut National de Recherche Biomedicale, Kinshasa, Democratic Republic of the Congo.
Jean Paul KompanyInstitut National de Recherche Biomedicale, Kinshasa, Democratic Republic of the Congo.
Merly TambuInstitut National de Recherche Biomedicale, Kinshasa, Democratic Republic of the Congo.
Kamy MuseneInstitut National de Recherche Biomedicale, Kinshasa, Democratic Republic of the Congo.
Patrick MukadiInstitut National de Recherche Biomedicale, Kinshasa, Democratic Republic of the Congo.ORCID 0000-0001-9312-9345
Placide MbalaInstitut National de Recherche Biomedicale, Kinshasa, Democratic Republic of the Congo.
Adva GadothDepartment of Epidemiology, UCLA Fielding School of Public Health, University of California, Los Angeles, Los Angeles, California, United States of America.ORCID 0000-0002-3217-2435
Brandyn R WestDepartment of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, United States of America.ORCID 0000-0002-1399-0117
Benoit Kebela IlungaDirectorate of Disease Control, Ministry of Public Health, Kinshasa, Democratic Republic of the Congo.
Didine KabaKinshasa School of Public Health, Kinshasa, Democratic Republic of the Congo.
Jean Jacques Muyembe-TanfumInstitut National de Recherche Biomedicale, Kinshasa, Democratic Republic of the Congo.
Nicole A HoffDepartment of Epidemiology, UCLA Fielding School of Public Health, University of California, Los Angeles, Los Angeles, California, United States of America.
Anne W RimoinDepartment of Epidemiology, UCLA Fielding School of Public Health, University of California, Los Angeles, Los Angeles, California, United States of America.ORCID 0000-0002-0662-9067
Erica Ollmann SaphireCenter for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, California, United States of America.ORCID 0000-0002-1206-7451
National Institute of Biomedical Research · CDUniversity of California, Los Angeles · USLa Jolla Institute for Immunology · USMinistry of Public Health · CDScripps Research Institute · US

Funding

Specific and Broadly Active Monoclonal Antibody Therapeutics Against The FilovirusesU19AI142790 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI SAPHIRE, ERICA OLLMANN · 2019 to 2023
$40.0M
NIAID NIH HHS U19 AI142790
6 · The paper itself

Abstract

Although multiple antigenically distinct ebolavirus species can cause human disease, previous serosurveys focused on only Zaire ebolavirus (EBOV). Thus, the extent of reactivity or exposure to other ebolaviruses, and which sociodemographic factors are linked to this seroreactivity, are unclear. We conducted a serosurvey of 539 healthcare workers (HCW) in Mbandaka, Democratic Republic of the Congo, using ELISA-based analysis of serum IgG against EBOV, Sudan ebolavirus (SUDV) and Bundibugyo ebolavirus (BDBV) glycoproteins (GP). We compared seroreactivity to risk factors for viral exposure using univariate and multivariable logistic regression. Seroreactivity against different GPs ranged from 2.2-4.6%. Samples from six individuals reacted to all three species of ebolavirus and 27 samples showed a species-specific IgG response. We find that community health volunteers are more likely to be seroreactive against each antigen than nurses, and in general, that HCWs with indirect patient contact have higher anti-EBOV GP IgG levels than those with direct contact. Seroreactivity against ebolavirus GP may be associated with positions that offer less occupational training and access to PPE. Those individuals with broadly reactive responses may have had multiple ebolavirus exposures or developed cross-reactive antibodies. In contrast, those individuals with species-specific BDBV or SUDV GP seroreactivity may have been exposed to an ebolavirus not previously known to circulate in the region.

Indexed as

EbolavirusHemorrhagic Fever, EbolaAntibodies, ViralDemocratic Republic of the CongoGlycoproteinsHealth PersonnelHumansImmunoglobulin GAntibodies, ViralGlycoproteinsImmunoglobulin G

Identifiers

PMID35255093
PMCPMC8929691
OpenAlexW4221032862

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.